[A16-01] Pertuzumab - Addendum to Commission A15-34
Last updated 18.02.2016
Project no.:
A16-01
Commission:
Commission awarded on 14.01.2016 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-41 | Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A15-34 | Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A22-103 | Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-102 | Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2016-02-18 A G-BA decision was published.